In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.


The free consultation period for this content is over.

It is now only available year-round to ESC Professional Members, Fellows of the ESC, and Young combined Members

Effects of once-weekly exenatide on clinical outcomes in the subgroup of patients with pre-existing cardiovascular disease: insights from EXSCEL

Session Management of coronary disease: temporal trends and residual risk

Speaker Robert Mentz

Congress : ESC Congress 2018

  • Topic : coronary artery disease, acute coronary syndromes, acute cardiac care
  • Sub-topic : Coronary Artery Disease - Clinical
  • Session type : Abstract Session
  • FP Number : 5257

Authors : RJ Mentz (Durham,US), VP Thompson (Durham,US), SM Gustavson (Gaithersburg,US), N Iqbal (Gaithersburg,US), P Ohman (Gaithersburg,US), RR Holman (Headington,GB), AF Hernandez (Durham,US)

Authors:
R.J. Mentz1 , V.P. Thompson1 , S.M. Gustavson2 , N. Iqbal2 , P. Ohman2 , R.R. Holman3 , A.F. Hernandez1 , 1Duke University Medical Center - Durham - United States of America , 2AstraZeneca Research and Development - Gaithersburg - United States of America , 3Oxford Centre for Diabetes - Oxford - United Kingdom ,

On behalf: EXSCEL Study Group

Citation:
European Heart Journal ( 2018 ) 39 ( Supplement ), 1082

Background: EXSCEL showed a non-significant reduction in major adverse cardiovascular events (MACE) and a nominally significant reduction in all-cause mortality when once-weekly exenatide was added to usual care for type 2 diabetes. A pre-specified subgroup analysis of treatment effects for the primary endpoint of MACE and other EXSCEL cardiovascular (CV) outcomes was performed in patients with known CV disease at baseline.

Methods: We evaluated outcomes by treatment group in the EXSCEL trial for the 10,782 participants (73% of the trial population) with known CV disease, i.e. history of major clinical manifestation of coronary artery disease, ischemic cerebrovascular disease or atherosclerotic peripheral arterial disease. Cox proportional hazards were used to compare the impact of once-weekly exenatide with placebo therapy on MACE, all-cause death, CV-related death, myocardial infarction, stroke, hospitalization for acute coronary syndrome (hACS) and hospitalization for heart failure.

Results: Patients in the exenatide group demonstrated a 10% relative risk reduction for MACE (HR, 0.90, 95% confidence interval 0.816 to 0.999, nominal p-value 0.047). Each of the secondary endpoints favored exenatide, compared with placebo, with the exception of hACS [Hazard Ratio (HR), 1.03], but none met the nominal level of statistical significance (all nominal P>0.05) (Figure).

Conclusion: Exenatide once-weekly reduced the risk of MACE in a subgroup of patients with pre-existing CV disease in EXSCEL with no new or overall safety concerns.

The free consultation period for this content is over.

It is now only available year-round to ESC Professional Members, Fellows of the ESC, and Young combined Members



Based on your interests

Three reasons why you should become a member

Become a member now
  • 1Access your congress resources all year-round on the New ESC 365
  • 2Get a discount on your next congress registration
  • 3Continue your professional development with free access to educational tools
Become a member now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are